
OMER
Healthcare · Biotechnology · $1.27B market cap
$17.49-0.50 (-2.8%)Nov 13, 4:00 PM EST
Next report
After the close
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · +92.6% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 16, 2026 · upcoming | After the close | -0.05 | — | — |
| Aug 12, 2026 | After the close | -0.27 | 0.02 | +107.4% |
| May 13, 2026 | After the close | -0.39 | 0.57 | +246.2% |
| Mar 3, 2026 | Time not confirmed | -0.52 | -0.55 | -5.0% |
| Nov 13, 2025 | After the close | -0.48 | -0.32 | +33.3% |
| Aug 14, 2025 | After the close | -0.55 | -0.53 | +3.6% |
| May 15, 2025 | After the close | -0.58 | -0.65 | -12.1% |
| Mar 31, 2025 | Before the open | -0.71 | -0.55 | +22.5% |
| Nov 13, 2024 | After the close | -0.77 | -0.64 | +16.9% |
| Aug 7, 2024 | After the close | -1.01 | -1.12 | -10.9% |
| May 15, 2024 | After the close | -0.63 | -0.75 | -19.0% |
| Mar 26, 2024 | Before the open | -0.55 | -0.15 | +72.7% |
| Nov 9, 2023 | After the close | -0.66 |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat…
| -0.82 |
| -24.2% |
| Aug 9, 2023 | Before the open | -0.53 | -0.70 | -32.1% |
| May 9, 2023 | After the close | -0.57 | -0.63 | -10.5% |
| Mar 13, 2023 | After the close | -0.57 | 2.05 | +459.6% |
| Nov 9, 2022 | After the close | -0.58 | -0.87 | -50.0% |
| Aug 9, 2022 | After the close | -0.66 | -0.66 | 0.0% |
| May 10, 2022 | After the close | -0.69 | -0.53 | +23.2% |
| Mar 1, 2022 | After the close | -0.36 | -0.37 | -2.8% |
| Nov 9, 2021 | After the close | -0.47 | -0.36 | +23.4% |
| Aug 9, 2021 | After the close | -0.55 | -0.46 | +16.4% |
| May 10, 2021 | After the close | -0.51 | -0.57 | -11.8% |
| Mar 1, 2021 | After the close | -0.69 | -0.60 | +13.0% |
| Nov 9, 2020 | After the close | -0.49 | -0.34 | +30.6% |
| Aug 10, 2020 | After the close | -0.59 | -0.61 | -3.4% |
| May 11, 2020 | After the close | -0.34 | -0.53 | -55.9% |
| Mar 2, 2020 | After the close | -0.50 | -0.58 | -16.0% |
| Nov 12, 2019 | After the close | -0.41 | -0.33 | +19.5% |
| Aug 8, 2019 | After the close | -0.44 | -0.29 | +34.1% |
| May 9, 2019 | After the close | -0.47 | -0.50 | -6.4% |
| Mar 1, 2019 | Before the open | -0.81 | -0.21 | +74.1% |
| Nov 8, 2018 | After the close | -0.71 | -0.81 | -14.1% |
| Aug 9, 2018 | After the close | -0.62 | -0.70 | -12.9% |
| May 10, 2018 | After the close | -0.59 | -0.62 | -5.1% |
| Mar 1, 2018 | After the close | -0.17 | -0.34 | -100.0% |